Recruiting

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(19 sites)

United States

The Ohio State University (OSU) Wexner Medical Center, Columbus, Ohio

Vanderbilt University Medical Centre, Nashville, Tennessee

Houston Methodist Hospital, Houston, Texas

Belgium

UZ Leuven, Leuven

Canada

Sunnybrook Health Sciences Centre, Toronto, Ontario

Italy

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan

Netherlands

Amsterdam UMC, Amsterdam

Poland

NEURO-CARE Sp. z o.o. Sp. Komandytowa, Katowice

Neurologia Slaska Centrum Medyczne, Katowice

Uniwersyteckie Centrum Kliniczne, SUM w Katowicach, Katowice

Euromedis Sp. z o.o., Szczecin

Centrum Medyczne NeuroProtect Sp z o.o., Warsaw

Mazowiecki Szpital Brodnowski Sp. z o. o., Warsaw

Spain

Hospital Clinic Barcelona, Barcelona

Hospital Universitari i Politecnic La Fe, Valencia

Sweden

Skåne University Hospital, Lund

United Kingdom

Cambridge University Hospitals NHS Foundation Trust, Cambridge

University Hospital of Wales, Cardiff

University College London Hospitals, London